Forest Laboratories, Inc. and Gedeon Richter Plc Announce Results from a Phase II Study of Cariprazine for the Treatment of Bipolar Depression
Orphagen Pharmaceuticals Awarded Phase 2 SBIR Funding to Investigate Novel Drug Class for CNS Disorders
Clients in focus...
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us